Trial · NCT02606305
Results by group969
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 969
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | Any TEAE | 3 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | Any TEAE | 126 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | Any TEAE | 4 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | Any TEAE | 4 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | Any TEAE | 10 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | Any TEAE | 4 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | Any TEAE | 4 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | Any TEAE | 7 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | Any TEAE | 4 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | Any TEAE | 56 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine + Bevacizumab + Carboplatin | Any TEAE | 41 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | SAEs | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | SAEs | 49 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | SAEs | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | SAEs | 4 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | SAEs | 3 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | SAEs | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | SAEs | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | SAEs | 3 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | SAEs | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02606305/results